Literature DB >> 23761659

Clinical disease upregulates expression of CD40 and CD40 ligand on peripheral blood mononuclear cells from cattle naturally infected with Mycobacterium avium subsp. paratuberculosis.

M S Khalifeh1, J R Stabel.   

Abstract

CD40 and CD40 ligand (CD40L) have costimulatory effects as part of a complex series of events in host immunity. In this study, the expression of CD40 and CD40L on peripheral blood mononuclear cells (PBMCs) isolated from cattle with Johne's disease were measured on freshly isolated PBMCs and on cells cultured for 8, 24, and 72 h in the presence or absence of live Mycobacterium avium subsp. paratuberculosis and exogenous gamma interferon, interleukin 10, and transforming growth factor β. Results demonstrated greater CD40 and CD40L expression on fresh PBMCs obtained from animals in the clinical stage of disease (symptomatic) than those from healthy control animals or cows in the subclinical stage of disease (asymptomatic). A similar expression profile with greater magnitude was noted for cultured PBMCs, with increased CD40 expression after 8 and 24 h of culture and increased CD40L expression between 24 and 72 h on PBMCs obtained from clinically infected animals. The addition of live M. avium subsp. paratuberculosis to cell cultures resulted in downregulation of CD40L expression in naturally infected cows, regardless of the disease stage. In contrast, the addition of live M. avium subsp. paratuberculosis to cultures resulted in upregulation of CD40 expression on cells obtained from clinically infected animals, while a decrease in expression was noted for healthy and subclinically infected cows. No effects of exogenous cytokines on CD40 or CD40L expression were observed. These results clearly point for the first time to a disparity in the expression of these costimulatory molecules on immune cells from cattle in different stages of Johne's disease and suggest further investigation into their roles in paratuberculosis pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23761659      PMCID: PMC3754516          DOI: 10.1128/CVI.00246-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  35 in total

1.  B cells activated via CD40 and IL-4 undergo a division burst but require continued stimulation to maintain division, survival and differentiation.

Authors:  J S Rush; P D Hodgkin
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

Review 2.  The CD40/CD154 receptor/ligand dyad.

Authors:  U Schönbeck; P Libby
Journal:  Cell Mol Life Sci       Date:  2001-01       Impact factor: 9.261

3.  Distinct profiles of human B cell effector cytokines: a role in immune regulation?

Authors:  Martin E Duddy; Andrea Alter; Amit Bar-Or
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

4.  CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets.

Authors:  U Thienel; J Loike; M J Yellin
Journal:  Cell Immunol       Date:  1999-12-15       Impact factor: 4.868

5.  Interaction of Mycobacterium tuberculosis-induced transforming growth factor beta1 and interleukin-10.

Authors:  C Othieno; C S Hirsch; B D Hamilton; K Wilkinson; J J Ellner; Z Toossi
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

6.  Cytokine gene expression in ileal tissues of cattle infected with Mycobacterium paratuberculosis.

Authors:  H Lee; J R Stabel; M E Kehrli
Journal:  Vet Immunol Immunopathol       Date:  2001-09-28       Impact factor: 2.046

7.  CD5-positive and CD5-negative human B cells converge to an indistinguishable population on signalling through B-cell receptors and CD40.

Authors:  A Gagro; N McCloskey; A Challa; M Holder; G Grafton; J D Pound; J Gordon
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

Review 8.  Mycobacterium paratuberculosis and the bovine immune system.

Authors:  P M Coussens
Journal:  Anim Health Res Rev       Date:  2001-12       Impact factor: 2.615

Review 9.  Intracellular trafficking of Mycobacterium avium ss. paratuberculosis in macrophages.

Authors:  N F Cheville; J Hostetter; B V Thomsen; F Simutis; Y Vanloubbeeck; E Steadham
Journal:  Dtsch Tierarztl Wochenschr       Date:  2001-06

10.  Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production.

Authors:  Hélène Gary-Gouy; Julie Harriague; Georges Bismuth; Cornelia Platzer; Christian Schmitt; Ali H Dalloul
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

View more
  5 in total

1.  MicroRNA expression profiling in PBMCs of Indian water Buffalo (Bubalus bubalis) infected with Brucella and Johne's disease.

Authors:  Jasdeep Singh; Jasdeep Kaur Dhanoa; Ratan K Choudhary; Amarjit Singh; Ram Saran Sethi; Simarjeet Kaur; Chandra Sekhar Mukhopadhyay
Journal:  ExRNA       Date:  2020-05-22

2.  Self-assembled particulate vaccine elicits strong immune responses and reduces Mycobacterium avium subsp. paratuberculosis infection in mice.

Authors:  Sandeep K Gupta; Natalie A Parlane; Dongwen Luo; Bernd H A Rehm; Axel Heiser; Bryce M Buddle; D Neil Wedlock
Journal:  Sci Rep       Date:  2020-12-18       Impact factor: 4.379

3.  Genome-wide association analyses identify genotype-by-environment interactions of growth traits in Simmental cattle.

Authors:  Camila U Braz; Troy N Rowan; Robert D Schnabel; Jared E Decker
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

4.  Transcriptional Profiling of Ileocecal Valve of Holstein Dairy Cows Infected with Mycobacterium avium subsp. Paratuberculosis.

Authors:  Randy J Hempel; John P Bannantine; Judith R Stabel
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

5.  Exogenous Vitamin D3 Modulates Response of Bovine Macrophages to Mycobacterium avium subsp. paratuberculosis Infection and Is Dependent Upon Stage of Johne's Disease.

Authors:  Taylor L T Wherry; Rohana P Dassanayake; Eduardo Casas; Shankumar Mooyottu; John P Bannantine; Judith R Stabel
Journal:  Front Cell Infect Microbiol       Date:  2022-01-17       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.